At ASCO 2022, Chinese biotech firms deliver rosy data on PD-(L)1, cell therapy
Elise Mak · 06/23/2022
Companies such as Henlius, OriCell, CStone, Gracell and Junshi presented clinical data from their PD-(L)1, cell therapy and other candidates. Henlius impresses with ES-SCLC data, Junshi boasts BTLA-targeted drug and OriCell flaunts GPRC5D-directed CAR-T
Cell therapy developer TCRCure bags over $47M to support R&D in the U.S. and China; CellOrigin, SciNeuro, Legend Biotech - News of the day
Elise Mak · 02/16/2022
TCRCure said it has secured over RMB 300 million from investors to advance and expand its cell therapy pipeline, and to support the simultaneous development of its programs in the U.S. and China. More news from CellOrigin, SciNeuro, Legend Biotech, CellOrigin, SciNeuro, Legend Biotech, Signature Biotech, Neuragen and MingMed.
China defines cell therapy as drug with new GMP
Minhua Chu · 01/24/2022
The release of good manufacturing practices for cell therapy this year is an important step in regulating cell therapies.
Neukio CEO: Make cell therapy allogenic, accessible and effective in solid tumors
Elise Mak · 12/22/2021
After launching the first CAR-T therapy on China market, Richard Wang wants to stay on the R&D frontier to push for safer, more affordable and efficacious cell therapies for more patients with the iPSC-CAR-NK technology. To succeed, emphasizing innovation and CMC early on is key, he told PharmaDJ.
China emphasizes clinical value while the U.S. reviews cell therapy with caution, regulators say
Elise Mak · 11/22/2021
At the 2021 China Cancer Immunotherapy Workshop, Wang Tao from China’s CDE and Jia Yuxia from the U.S. FDA each shared the Chinese and U.S. regulators’ considerations when reviewing new therapies. Wang said the CDE emphasizes clinical value to address unmet medical needs, while Jia explained the FDA’s clinical assessment for cell therapy.
September fundraising puts cell therapy and immuno-oncology in the spotlight
PharmaDJ · 10/15/2021
Chinese drugmakers closed 33 financing rounds in September, raising over $1.05 billion. Oncolytic virus therapies developer Virogin Biotech and two CAR-T therapy developers were the biggest fundraisers.
IASO bags $108M Series C to advance cell therapy
Elise Mak · 09/17/2021
The CAR-T therapy developer has raised more than $178 million since its establishment in 2017.
Cytovia and its China JV secures $45M to develop NK cell therapy
Elise Mak · 09/15/2021
Cytovia Therapeutics and its Chinese joint venture CytoLynx Therapeutics have raised $45 million to move their cell therapy candidates to IND stage and support the trials.
mRNA and iPSC attract investments in July
PharmaDJ · 09/10/2021
Chinese drug developers continued to close more financing deals for the fourth consecutive month.
Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback:   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement